Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Anthropic's Scott White explains how AI agents evolved from chatbots to autonomous workers at VentureBeat Transform 2025, cutting enterprise tasks from weeks to minutes.

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

A new study led by Johns Hopkins researchers has identified a significant gap between the number of U.S. patients for whom cholesterol-lowering drugs ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...